Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Technology's central role in human life has drawn concerns and backlash. The backlash against technology is not a uniform movement and encompasses many heterogeneous ideologies. The earliest known revolt against technology was Luddism, a pushback against early automation in textile production. Automation had resulted in a need for fewer workers, a process known as technological unemployment. Between the 1970s and 1990s, American terrorist Ted Kaczynski carried out a series of bombings across America and published the Unabomber Manifesto denouncing technology's negative impacts on nature and human freedom. The essay resonated with a large part of the American public. It was partly inspired by Jacques Ellul's The Technological Society. Some subcultures, like the off-the-grid movement, advocate a withdrawal from technology and a return to nature. The ecovillage movement seeks to reestablish harmony between technology and nature.
In Syria, most Druze reside in the As-Suwayda Governorate, which encompasses almost all of Jabal al-Druze. This governorate is unique in Syria as it has a Druze majority. Additionally, it has integrated Christian communities that have long coexisted harmoniously with the Druze in these mountain. In the 1980s Druze made up 87.6% of the population, Christians (mostly Greek Orthodox) 11% and Sunni Muslims 2%. In 2010, the As-Suwayda governorate has a population of about 375,000 inhabitants, Druze made up 90%, Christians 7% and Sunni Muslims 3%. Due to low birth and high emigration rates, Christians proportion in As-Suwayda had declined. The Druze form a majority in the Jabal Hauran, which is part of the al-Suwayda Governorate. There is a significant Christian population, both Greek Orthodox and Greek Catholic (Melkite), in the Hauran region as a whole, though most Christians are concentrated in the towns and villages straddling the western foothills of Jabal Hauran. Most of the Christians of Jabal Hauran are descents of the Ghassanids (Arab tribe). A major component of the Azd tribal confederation, the Ghassanids established themselves in Arabia Province and like the Salihids, embraced Christianity. The Byzantine era in the Hauran was marked by the dual processes of rapid Arabization and the growth of Christianity. According to the historian Kamal al-Shofani "Christians inhabited the region before the Druze, and some of them came to Jabal al-Druze (Mountain of the Druze) at the end of the 17th century, fleeing Ottoman oppression".
==== Structure ==== A eukaryotic cell has a cell membrane that surrounds a gel-like cytoplasm. The cytoplasm contains the cytoskeleton, the cell nucleus, the endoplasmic reticulum, ribosomes, the Golgi apparatus, mitochondria, peroxisomes, endosomes, vacuoles and vesicles, and vaults. A eukaryotic cell structure, includes an endomembrane system encompassing the cell membrane, and all the membranes of the organelles excluding those of the mitochondria. The whole system cooperates in the modification, packaging, and transport of proteins and lipids.
The renamed USS Pastores and USS Calamares were taken over by the United States Navy in World War I and used to take troops and refrigerated supplies to and from Europe. After hostilities ceased they were returned to United Fruit Company in 1919. They were requisitioned again on 2 June 1941 from United Fruit for use in World War II. After hostilities ceased they were then returned again to United Fruit Company in 1946.
=== Human trafficking === Human trafficking is a modern form of slavery where people are forced, tricked, or pressured into working or doing sexual acts. It can happen anywhere and affect anyone, no matter their age, race, or background.
Sources: en.wikipedia.org
== Further reading == Abbott, Andrew (2001). Chaos of Disciplines. University of Chicago Press. ISBN 978-0-226-00101-2. Oleson, Alexandra; Voss, John (1979). The Organization of knowledge in modern America, 1860–1920. Johns Hopkins University Press. ISBN 0-8018-2108-8. US Department of Education Institute of Education Sciences. Classification of Instructional Programs (CIP). National Center for Education Statistics.
==== FASTER ==== The FASTER algorithm uses a combination of deterministic and stochastic criteria to optimize amino acid sequences. FASTER first uses DEE to eliminate rotamers that are not part of the optimal solution. Then, a series of iterative steps optimize the rotamer assignment.
Its ability to regulate adhesion, migration, proliferation, immune regulation, and ECM remodeling makes it an important contributor in normal tissue development, homeostasis, and repair while also having a part in pathological processes such as fibrosis, inflammation, and cancer. The diverse roles of ITGA1 highlight its importance as both a mediator of tissue homeostasis and a potential target for diseases driven by abnormal cell-ECM interactions.
In recent years, the clinical understanding of the FDA's "black box" warning has evolved to focus on the balance between medication risks and the risks of untreated depression. While the 2004 and 2006 warnings regarding increased suicidal ideation in children and young adults (under 25) remain, long-term data published through 2024 suggests that these warnings may have led to an unintended decline in depression treatment, which some studies correlate with an increase in suicide deaths among adolescents. Statistical meta-analyses updated in 2022 confirm that while the risk of suicidal thoughts in youth on antidepressants like fluoxetine is approximately twice that of a placebo (4% vs 2%), there remains no statistically significant increase in completed suicides across dozens of pediatric trials. Furthermore, recent data continues to show a protective effect in older populations; for adults aged 65 and older, antidepressant use is associated with a statistically significant decrease in suicidality. Regarding specific treatments, research published between 2021 and 2023 reinforces that fluoxetine is most effective and carries the lowest risk of adverse behavioral events when paired with psychotherapy. A 2022 meta-analysis found that combination therapy (medication plus CBT) resulted in a lower incidence of suicidal events compared to fluoxetine alone.
==== Depreciation tax deduction ==== For qualified production property of a taxpayer, the law makes permanent a 100% Section 179 depreciation deduction for the adjusted basis for the property acquired after January 19, 2025. Businesses are allowed to take a section 179 tax deduction for the cost of certain business property, software, leasehold improvements, and water utility property rather than deduct only the amount depreciated each year. Under the law, the maximum tax deduction is permanently increased from $1 million to $2.5 million and then phased out to $4 million, all of which will be indexed for inflation in future years. These changes are effective for tax years beginning after December 31, 2024. The law also created a new depreciation allowance for nonresidential real property that is used as an essential part of an activity that includes the manufacturing, production, or refining of certain tangible products that significantly transforms the product. Types of property that do not qualify include nonresidential real property used for offices, administrative services, lodging, parking, sales activities, software development, and software engineering. The property's construction must begin between January 20, 2025, and December 31, 2028, and it must be placed in service in the U.S. or U.S. possessions on or before December 31, 2030.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.